论文部分内容阅读
目前已发现594种表皮生长因子受体(epidermal growth factor receptor,EGFR)突变类型,其中95%以上的突变存在于编码酪氨酸激酶结构域的基因的18~21外显子中.在总突变中,Del19(19号外显子缺失突变)与L858R(21号外显子点突变)突变约占84. 60% ,被确认为EGFR-TK敏感突变.其余突变包括:G719X(18号外显子点突变),E709X(18号外显子点突变),Del18(18号外显子缺失突变),Ins19(19号外显子插入突变),Ins20(20号外显子插入突变), L861Q(21号外显子点突变)等为非经典突变,约占总突变形式的12. 10% .非小细胞肺癌(non-small cell lung cancer,NSCLC)EGFR各类型非经典突变对不同EGFR-TKIs治疗的反应差别很大,因此,了解EGFR非经典突变对靶向治疗的反应,对存在非经典突变的NSCLC患者的治疗具有重大意义.本文对NSCLC各个EGFR非经典突变的类型及针对此类突变的靶向治疗进展进行综述,以期为临床治疗提供参考.“,”At present, there are 594 types of epidermal growth factor receptor (EGFR) mutations, of which more than 95% exist in exon 18-21 of the gene encoding tyrosine kinase (TK) domain. The mutations of Del19 and L858R account for 84. 60% of the total mutations and are considered to be EGFR-TK sensitive mutations. Other mutations include G719X, E709X, Del18, Ins19, Ins20, L861Q, etc. which are uncommon mutations, accounting for 12. 10% of the total mutations. The response of uncommon EGFR muta-tions in non-small cell lung cancer ( NSCLC) to EGFR-TKIs treatment varies greatly. Therefore, it is of great significance to under-stand the response of uncommon EGFR mutations to targeted therapies for NSCLC patients with uncommon mutations. In order to pro-vide experience for clinical treatment, the types of uncommon EGFR mutations and targeted therapies aiming to those mutations were reviewed in this paper.